Core Viewpoint - The company held its second special meeting of independent directors in 2025, where it approved the proposal to postpone certain fundraising investment projects, aligning with the company's operational needs and strategic development [1]. Group 1 - The meeting was convened on June 18, 2025, with all three independent directors present, complying with relevant laws and regulations [1]. - The decision to postpone some fundraising projects was deemed necessary based on the company's actual situation and was found to not harm shareholder interests [1]. - The proposal was unanimously approved with a vote of 3 in favor, 0 against, and 0 abstentions, indicating strong support from the independent directors [1].

Group 1 - The company held its seventh meeting of the sixth supervisory board on June 19, 2025, with all three supervisors present, confirming the meeting's legality and validity [1][2] - The supervisory board approved the postponement of certain fundraising investment projects, stating that this decision aligns with the company's operational status and long-term development plan, and does not harm shareholder interests [1][2] - The postponement does not involve any changes to the implementation subjects or directions of the raised funds, and it will not significantly impact the company's current production and operations [1]

Core Viewpoint - The company, Shandong Kehui Power Automation Co., Ltd., has announced a delay in some of its fundraising projects, which is a prudent decision based on the actual progress of the projects and does not alter the investment content or total amount [2][6]. Fundraising Basic Situation - The company successfully issued 26.17 million shares at a price of RMB 19,282,662.77, resulting in a net fundraising amount of RMB 45,623,360.81 as of May 31, 2025 [2][3]. Fund Usage Status - The fundraising projects include the "Smart Grid Fault Monitoring and Automation Product Upgrade Project" and the "Modern Electrical Automation Technology Research Institute Construction Project," with specific funding amounts and progress reported [4][5]. Delay of Fundraising Projects - The company plans to postpone the expected completion dates for the projects to December 2025 due to the need for synchronization in project implementation and ongoing construction progress [5][6]. Measures to Ensure Completion - The company will adhere to relevant regulations and strengthen supervision over the use of fundraising, ensuring that the projects are completed on time despite the delays [6][7]. Impact of Delay - The delay is not expected to have a significant adverse effect on the company's normal operations or long-term development plans, as it does not change the investment direction or harm shareholder interests [6][8]. Review Procedures - Both the board of directors and the supervisory board have approved the delay, confirming that the decision complies with regulatory requirements and does not harm shareholder interests [6][7].

Meeting Overview - The third meeting of the Supervisory Board of Hangzhou Anjisi Medical Technology Co., Ltd. was held on June 17, 2025, with all three supervisors present, complying with relevant laws and regulations [1]. Resolutions Passed - The Supervisory Board approved the proposal to grant restricted stock to three eligible incentive objects under the 2025 Restricted Stock Incentive Plan at a price of 46.16 yuan per share, totaling 16,089 shares [1][2]. - The Supervisory Board approved the proposal to postpone certain fundraising investment projects, stating that the decision was made based on the actual construction situation and did not harm shareholders' interests [2]. - The Supervisory Board approved the use of self-owned foreign exchange funds to pay for the required funds for fundraising projects, with a plan to replace the amount with raised funds, ensuring compliance with relevant regulations and improving fund utilization efficiency [3].

证券代码：601689 证券简称：拓普集团 公告编号：2025-058 宁波拓普集团股份有限公司 第五届监事会第十九次会议决议公告 第1号——规范运作》等规范性文件的规定。该事项的相关决策程序符合中国证 监会、上海证券交易所的相关规定。因此，监事会一致同意该事项。 宁波拓普集团股份有限公司（以下简称"公司"）第五届监事会第十九次会 议于 2025 年 6 月 17 日 10 时在公司总部 C-105 会议室以现场会议方式召开，会 议通知已于 2025 年 6 月 6 日以通讯方式发出。本次会议由监事会主席颜群力先 生召集并主持，应出席监事三名，实际出席监事三名。会议的召集、召开及表决 程序符合《中华人民共和国公司法》及《公司章程》的规定。 二、 监事会会议审议情况 （一）审议通过了《关于变更部分募集资金用途的议案》 监事会经审议后认为：公司本次变更部分募集资金用途是从合理利用资金的 角度出发做出的调整，符合公司战略规划和实际发展情况，有利于提高募集资金 使用效率，未发现有损害公司和股东利益的情形，符合《上市公司募集资金监管 规则》 《上海证券交易所股票上市规则》 《上海证券交易所上市公司自律监管指引 本公司监 ...

Group 1 - The company held its 17th meeting of the 3rd Supervisory Board on June 20, 2025, with all three supervisors present, complying with relevant laws and regulations [1][2] - The Supervisory Board unanimously approved the proposal regarding the postponement of fundraising investment projects, indicating that this decision is based on the actual implementation situation and will not adversely affect the company's normal operations [2] - The voting results for the proposal were 3 votes in favor, 0 votes against, and 0 abstentions, demonstrating full support from the Supervisory Board [2] Group 2 - The postponement of fundraising investment projects is deemed a prudent decision by the company, ensuring that there will be no significant negative impact on the company or its shareholders [2] - The company will provide further details regarding the postponement in a separate announcement published on the Shanghai Stock Exchange website [2]

在营收下降之时，上海沿浦（605128）(605128.SH)实际控制人开启套现模式。 实控人拟减持不超633万股 从一家小厂，到将公司打造成上市企业，周建清瞄准了汽车行业的未来。不过，当前他欲大额减持公司 股份。 6月18日晚间，上海沿浦发布公告，公司控股股东、实际控制人周建清因个人资金需求，拟通过集中竞 价交易方式减持其所持有的公司股份合计不超过211万股，即不超过公司股份总数的0.9993%，拟通过 大宗交易方式减持其所持有的公司股份合计不超过422万股，即不超过公司股份总数的1.9987%，本次 合计减持不超过公司股份总数的2.9980%。也就是说，其通过集中竞价交易方式和大宗交易方式合计减 持不超过633万股。这也是其首次减持公司股份。 截止到公告披露日，周建清直接持有上海沿浦股份6773.27万股，占公司股份总数的32.08%。周建清不 存在一致行动人。上述股份均为公司IPO前取得的股份(3071.5万股)及公司上市后的历年权益分派时以 资本公积转增股本方式取得的股份(3701.77万股)，截至本公告披露日，6773.27万股均为无限售条件流 通股。 截至公告日收盘，上海沿浦股价达27.6元/股， ...

Group 1 - The company announced a delay in the completion dates for two fundraising investment projects, moving the expected operational status from June 2025 to June 2026 [1] - The projects affected are the "Pharmaceutical Liquid Preparation System Production Center Construction Project" and the "Pharmaceutical R&D Service Platform Upgrade and Expansion Project" [1] - The delay does not change the investment content, total amount, or implementing entity, and is not expected to have a substantial impact on project implementation or the company's normal operations [1] Group 2 - As of May 31, 2025, the company has cumulatively invested 164 million yuan in the fundraising projects, with a remaining balance of 109 million yuan in the fundraising account [1]

晨光生物（300138）公告，公司第五届董事会第十七次会议、第五届监事会第十六次会议审议通过了 《关于部分募集资金投资项目延期的议案》，同意对"天然植物综合提取一体化项目(一期)"、"营养药用 综合提取项目(一期)"及"赞比亚土地开发及配套设施建设项目"达到预定可使用状态的时间进行延期。延 期后的预计完成时间分别为2027年6月30日、2027年4月30日、2026年12月31日。延期原因为全球经济环 境变化、市场开拓缓慢、生产工艺持续优化等因素影响。公司将严格遵守相关规定，科学决策，加强监 督，确保募集资金使用的合法有效。本次延期不会对公司正常经营产生重大不利影响。 ...

| 项目名称 | 赵授人慕集资金会题 | 累计投入金額 | 投资进度(%) | 原计划理由达到预定可使用状 图书馆 | | --- | --- | --- | --- | --- | | 年产1000万件医用内冠绩设备及 图城项目 | 29,261.00 | 14,303.90 | 48.88 | 2025 4-3 H 31 日 | | 赞销服务因结丹级建设项目 | 11,210.80 | 6.478.88 | 57.79 | 2025年12月31日 | | 项目 ਸਿੰਘ | 颜计划项目达到预计可使用状态的包期 | | 调整后项目达到预期可使用状态日期 | | | 因创医疗器械研发中心项目 | 2005年6月30日 | | 2026年12月31日 | | | 程于禁制性股票数量(股) | 量提供的总量用(万元) | 2025年 10000000 | 2026年 (万元) | 2027 4 (万元) | | 项目名称 | 製投入嘉集资金金額(万元) | | --- | --- | | 年产1000万伴医用内寂寞设备及器械项目 | 29,261.00 | | 营销服务网络升级建设培目 | 11.210.80 | ...